No Data
Express News | Bio-Thera Solutions Partners With Tabuk Pharmaceuticals to Commercialize Bat2206, a Stelara® (Ustekinumab) Biosimilar in Saudi Arabia
Is Bio-Thera Solutions (SHSE:688177) A Risky Investment?
Bio-Thera Solutions Grants Costa Rican Pharma Firm Right to Market Autoimmune Drug
Express News | Bio-Thera Solutions Expands Partnership With Steincares in Latam With Addition of a Third Biosimilar to Partnership
Bio-Thera Solutions (688177.SH): Signed a licensing and production, supply, and commercialization agreement with SteinCares for BAT2306 (Sukuzimab) injection.
Globe News reported on December 16 that Bio-Thera Solutions (688177.SH) announced that it held the 20th meeting of the second Board of Directors on December 16, 2024. The meeting reviewed and approved the proposal regarding the signing of a license and production, supply, and commercialization agreement with SteinCares for BAT2306 (tucatinib) injection. The company has signed a license and commercialization agreement with Stein on March 18, 2024, to launch BAT2506 (golimumab) injection and BAT2606 (mepolizumab) injection in Brazil and the rest of the Americas.
Bio-thera solutions (688177.SH): The company's bevacizumab has not yet started selling in the European Union and the USA.
Ge Longhui 21st November丨Bio-Thera Solutions (688177.SH) stated on the interactive platform that the company's Bevacizumab monoclonal antibody has not yet started sales in the European Union and USA; TOFIDENCE (Tuzumab monoclonal antibody) started sales in the USA in May this year, and the listing time in the European Union is yet to be determined. Other overseas markets have not yet been approved for listing, and the company will actively follow up to promote the relevant processes. The company recognizes revenue in accordance with accounting standards, and part of the 10 million milestone from Hikma is included in the revenue. For specific information on the breakdown of revenue, please refer to the company's disclosure in the "Bio-Thera Solutions 2024 Interim Report" in statutory media.
Bio-Thera Solutions, Ltd.'s (SHSE:688177) 26% Price Boost Is Out Of Tune With Revenues
